About the study

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Max Age =17 years
2. Solid Tumors (except primary central nervous system malignant tumors): Patients must have a histopathologic confirmation of malignancy. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist
3. Non-Hodgkin's Lymphoma, limited to primary mediastinal B-cell lymphoma and anaplastic large cell lymphoma. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist.
4. Provision of diagnostic tumor sample mandated if available
5. Evaluable disease
6. No prior exposure to immune-mediated therapy
7. Adequate organ and marrow function
8. Life expectancy of at least 3 months

Exclusion criteria

1. History of allogeneic organ transplantation (exceptions may be allowed for NHL after discussion with Sponsor). History of autologous bone marrow transplant may be allowed (after discussion with Sponsor).
2. Active or prior documented autoimmune or inflammatory disorders (exceptions)
3. Uncontrolled intercurrent illness
4. History of primary immunodeficiency
5. Active infection including tuberculosis, hepatitis B, C or HIV
6. Any unresolved toxicity NCI CTCAE version 5.0 Grade ≥2 from previous anticancer therapy (exceptions)

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.